We look at some of the highlights of our Twitter chat (#TalkProteomics), where we questioned panelists John Wilson, Ben Orsburn, Matthias Trost and Eduardo Chicano Gálvez about all things proteomics – from mass spectrometry to drug discovery.
This editorial provides an insight into the advancing field of microsampling as a tool to monitor critically ill patients in the clinic, highlighting the need for further development to ensure patients receive the highest quality of care.
A novel protein has been discovered that could be a useful blood-based biomarker to monitor the progression of inherited Alzheimer’s disease, over a decade before the clinical symptoms appear.
A new molecular engineering method, termed TAC-seq, has been developed to enhance the precision of clinical biomarker analysis.
Researchers from Syracuse University (NY, USA) have developed a novel class of nanobiosensor that could detect, characterize and analyze protein–protein interactions in blood serum to assist in cancer detection.
Thermo Fisher Scientific (MA, USA) have announced the launch of a new complementary diagnostic immunoassay, the Thermo Scientific QMS Plazomicin Immunoassay, for measuring the concentration of a novel therapeutic antibiotic, plazomicin, used to treat complicated urinary tract infections.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
Development and validation of an electrochemiluminescent ELISA for quantitation of oral insulin tregopil in diabetes mellitus serum
This methodology discusses how a sensitive ELISA method could be used to support accurate measurement of Tregopil insulin and its metabolites.
Boehringer Ingelheim has announced that the interchangeability study for their adalimumab biosimilar candidate has begun.